NCT07805967 · RECRUITING
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This is a natural history study, not a treatment trial. Researchers are tracking how atypical parkinsonian conditions like multiple system atrophy, dementia with Lewy bodies, PSP, and corticobasal degeneration progress over time, looking at motor symptoms, imaging changes, and possible biomarkers. There is no drug or intervention being tested here, just careful observation to build a better picture of these diseases.
You may qualify if
- MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
- DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
- PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
- CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).
You're excluded if
- Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure .
- Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-09-08